Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

Next Previous
Trial Profile

A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms TITAN
  • Sponsors Ablynx

Most Recent Events

  • 14 Dec 2021 Results from TITAN, HERCULES and other studies, comparing patient-centered outcomes from Germany and Austria, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 18 Feb 2021 Data from this study and HERCULES were used for cost-effective analysis of caplacizumab for immune thrombotic thrombocytopenic purpura, published in the Blood.
  • 04 Dec 2018 Results analysing integrated efficacy from the individual Phase II (TITAN) and III(HERCULES) studies with Caplacizumab in patients with Acquired Thrombotic Thrombocytopenic Purpura presented at the 60th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top